Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

Pier Luigi Zinzani, Robert Chen, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

研究成果: Letter

元の言語English
ページ(範囲)950-954
ページ数5
ジャーナルLeukemia and Lymphoma
61
発行部数4
DOI
出版物ステータスPublished - 20-03-2020

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

これを引用

Zinzani, P. L., Chen, R., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Lin, J., Nahar, A., Balakumaran, A., & Moskowitz, C. H. (2020). Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leukemia and Lymphoma, 61(4), 950-954. https://doi.org/10.1080/10428194.2019.1702178